Table 1.
Author [reference] | Year | Patient age and sex | Diagnosis | Time between imatinib start and hepatotoxicity | Treatment | Outcome |
---|---|---|---|---|---|---|
Talpaz et al. [3] | 2002 | Not reported | CML | 6 days | Drug interruption | Death |
Lin et al. [4] | 2003 | 61 years, female | PV | 7 weeks | Drug interruption | Death |
Cross et al. [5] | 2006 | 46 years, female | CML | 77 weeks | LT | Death |
Ridruejo et al. [6] | 2007 | 51 years, female | CML | 20 weeks | Drug interruption | Death |
Thia et al. [7] | 2008 | 45 years, female | CML + chronic hepatitis B | 20 weeks | Drug interruption | Death |
Perini et al. [8] | 2009 | 47 years, female | CML | 72 weeks | LT | Survived |
Martínez Pascual et al. [9] | 2010 | 34 years, female | CML | 32 weeks | LT | Survived |
Harding et al. [2] | 2016 | 30 years, female | CML | 20 weeks | LT | Survived |
Present case | 2017 | 36 years, female | CML | 30 weeks | LT | Survived |
Abbreviations: CML chronic myeloid leukemia, PV Polycythemia vera, LT Liver transplant